Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from PureTech Health ( (GB:PRTC) ) is now available.
PureTech Health announced significant achievements in 2024, including FDA approval for Cobenfy™, positive Phase 2b results for deupirfenidone in IPF, and promising data for LYT-200 in cancer treatment. The company’s financial strength is underscored by a robust cash position, supporting operations through 2027. PureTech’s strategic focus is on advancing its pipeline, securing external funding for Phase 3 trials, and maintaining capital efficiency to drive long-term growth and shareholder value.
More about PureTech Health
PureTech Health is a biopharmaceutical company focused on developing innovative therapies for serious diseases. The company operates a unique hub-and-spoke model, advancing both wholly-owned programs and founded entities in areas such as idiopathic pulmonary fibrosis (IPF), schizophrenia, and cancer treatment. PureTech’s market focus includes leveraging its R&D engine to create impactful therapies and generate value for patients and shareholders.
YTD Price Performance: -16.91%
Average Trading Volume: 614,726
Technical Sentiment Signal: Buy
Current Market Cap: £299.8M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue